Development of radiolabelled compounds using reactor-produced radioisotopes

Our investigation ascertained the efficacy of radiopharmaceuticals developed by our research team with the applications into clinical studies and its unwanted effects on the aspects of quality control and safety concerns as well. According to our research, newly developed 166Ho-chitosan complex was verified as a very promising radiopharmaceutical in the future. Clinical studies further approved that its applications could be broadened out for the treatment of other diseases such as rheumatoid arthritis and liver cancer whose size is larger than 4 cm with highly effective manner compared to other radiopharmaceutical. Investigation on 166Ho-patch as a topical application for skin diseases proved its efficacy and safety through animal experiments. Its efficacy on the treatment of skin cancer was also confirmed by Raman spectrum. Also, 166Ho-Stent and 166Ho-Balloon were developed as one of the effective radioactive medical devices for a treatment of esophageal cancer and for an inhibition of restenosis, respectively. One of the most important achievements from present investigation was a development of 166Ho-coated balloon. With concerns of safety and efficiency related to the leakage of radioactive material into unwanted area due to the worst case of a balloon rupture when using a 166Ho-DTPA filled balloon, the concept of coating skill was introduced. Thereby, a coated balloon was developed and a significantly advanced its safety and efficacy of coated balloon were also affirmed by animal study. A development of radiopharmaceuticals such as 153Sm-CHICO and 188Re-HEDP were also carried out. Especially 53Sm is known to possess longer half-life than 166Ho, therefore, a concept was extended to develop 53Sm-chitosan complex with easy preparation procedure. Results approved theses radiopharmaceuticals could be useful in the treatment of radiosynovectomy, pain induced from metastasized bone cancer, respectively. All of these radiopharmaceuticals are characterized with high tissue specificity which helps a delivery of radionuclides to the infected area only. RI labelled polymeric nanosphered(<200nm) was also developed to establish a drug delivery system